PENGO, VITTORIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.353
EU - Europa 2.276
AS - Asia 2.215
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 8
SA - Sud America 3
Totale 24.865
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.331
CN - Cina 1.136
SG - Singapore 787
FI - Finlandia 478
DE - Germania 379
SE - Svezia 343
UA - Ucraina 292
IT - Italia 268
VN - Vietnam 226
GB - Regno Unito 196
FR - Francia 189
NL - Olanda 43
RU - Federazione Russa 34
IN - India 25
IE - Irlanda 21
CA - Canada 16
KR - Corea 13
JP - Giappone 11
EU - Europa 10
HK - Hong Kong 10
BE - Belgio 6
CZ - Repubblica Ceca 6
AU - Australia 4
GR - Grecia 4
MX - Messico 4
NZ - Nuova Zelanda 4
ES - Italia 3
HU - Ungheria 3
AT - Austria 2
CH - Svizzera 2
LT - Lituania 2
RO - Romania 2
BG - Bulgaria 1
BR - Brasile 1
EC - Ecuador 1
GT - Guatemala 1
IR - Iran 1
KW - Kuwait 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LV - Lettonia 1
PE - Perù 1
PR - Porto Rico 1
PT - Portogallo 1
TH - Thailandia 1
TR - Turchia 1
TW - Taiwan 1
Totale 24.865
Salva come PNG Salva come JPEG
Città #
Fairfield 3.552
Woodbridge 2.049
Houston 1.479
Ashburn 1.420
Chandler 1.357
Jacksonville 1.344
Cambridge 1.226
Seattle 1.221
Ann Arbor 1.205
Wilmington 1.193
Singapore 599
Princeton 562
Boardman 506
San Diego 366
Beijing 243
Santa Clara 229
Dong Ket 226
Nanjing 212
Medford 204
Roxbury 193
Des Moines 191
Helsinki 164
Guangzhou 109
Padova 85
Hebei 60
Nanchang 59
Shenyang 58
London 57
Norwalk 47
Jiaxing 42
New York 39
Redwood City 33
Changsha 32
Jinan 31
Falls Church 29
Frankfurt am Main 29
Ogden 27
Tianjin 25
Hefei 24
Dublin 19
Tappahannock 18
Kharkiv 17
Shanghai 17
Indiana 16
Kunming 15
Zhengzhou 14
Chicago 12
Milan 12
Dearborn 11
Ningbo 11
Rome 11
Seoul 11
Detroit 10
Hong Kong 10
Munich 10
Washington 10
Kilburn 9
Mestre 9
Borås 7
Nürnberg 7
Chiswick 6
Lanzhou 6
Orange 6
Prescot 6
Pune 6
Redmond 6
Rockville 6
Groningen 5
Los Angeles 5
Taiyuan 5
Vicenza 5
Brno 4
Brussels 4
Cagliari 4
Dallas 4
Edinburgh 4
Genoa 4
Haikou 4
New Bedfont 4
Taizhou 4
Tokyo 4
Toronto 4
Verona 4
Amsterdam 3
Athens 3
Bologna 3
Borgomanero 3
Budapest 3
Falkenstein 3
Ferrara di Monte Baldo 3
Geislingen an der Steige 3
Hanover 3
Las Vegas 3
Leawood 3
Mamoiada 3
Utrecht 3
Wandsworth 3
Acton 2
Aprilia 2
Auburn Hills 2
Totale 20.941
Salva come PNG Salva come JPEG
Nome #
The left atrial appendage: from embryology to prevention of thromboembolism 176
A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naive Patients with Non-Valvular Atrial Fibrillation 162
'Criteria' aPL tests: Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010 143
Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement. 137
Antibody profile and clinical course in primary anti phospholipid syndrome with pregnancy morbidity 134
Antibodies to Domain I of β2-Glycoprotein I are in Close Relation to Patients Risk Categories in Antiphospholipid Syndrome (APS) 131
Laboratory testing for antiphospholipid syndrome 131
A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty. 128
Diagnosis and therapy of antiphospholipid syndrome 128
A comparison of a moderate with moderate-high intensity oral anticoagulant treatment in patients with mechanical heart valve prostheses 124
Antiphospholipid syndrome: interpretation of laboratory data 123
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. 123
Prescription of vitamin K inhibitors in low-risk patients with atrial fibrillation 121
Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification 120
Circulating β2 glycoprotein I-IgG anti-β2 glycoprotein I immunocomplexes in patients with definite Antiphospholipid Syndrome. 120
The Paradox of the Lupus Anticoagulant: History and Perspectives 118
Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. 117
Interpretation of laboratory data and need for reference laboratories. 117
Antiphospholipid syndrome and the heart: A case series and literature review 117
An unusual acute coronary syndrome: undisclosed disease hidden under a confounding clinical presentation 117
Comparative classification of thrombotic formations on bileaflet mechanical heart valves by phonographic analysis 115
Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report 115
APS - Diagnostics and challenges for the future 113
Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review 111
A pharmacokinetic-pharmacodynamic model for individualisation of an oral anticoagulation therapy 111
Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant 110
The J-elongated conformation of β2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome 109
A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature. 108
An Approach to Differential Diagnosis of Antiphospholipid Antibody Syndrome and Related Conditions 108
A Bridging Protocol in High-Thrombotic Risk Mechanical Valve Bearers Undergoing Surgery or Invasive Procedures 108
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. 108
Lupus anticoagulant testing: Diluted Russell Viper Venom Time (dRVVT) 108
Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study 107
ANTIPHOSPHOLIPID ANTIBODIES ARE NOT PRESENT IN THE MEMBRANE OF GEL-FILTERED PLATELETS OF PATIENTS WITH IGG ANTICARDIOLIPIN ANTIBODIES, LUPUS ANTICOAGULANT AND THROMBOSIS 106
Immunosuppressive treatment in a heart transplantation candidate with antiphospholipid syndrome 106
Deep Venous Thrombosis After Surgery for Inflammatory Bowel Disease: Is Standard Dose Low Molecular Weight Heparin Prophylaxis Enough? 106
Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome 106
Dyspnoea in a young woman: the opposite of every truth is just as true 106
Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles 106
Antiphospholipid syndrome: critical analysis of the diagnostic path 105
The Redox Enzyme p66Shc Contributes to Diabetes and Ischemia-Induced Delay in Cutaneous Wound Healing 105
Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns 104
PURIFICATION OF ANTICARDIOLIPIN AND LUPUS ANTICOAGULANT ACTIVITIES BY USING CARDIOLIPIN IMMOBILIZED ON AGAROSE BEADS 102
Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. 102
BINDING OF AUTOIMMUNE CARDIOLIPIN-REACTIVE ANTIBODIES TO HEPARIN - A MECHANISM OF THROMBOSIS 101
Bileaflet mechanical heart valve closing sounds: in vitro classification by phonocardiographic analysis 101
VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study 101
Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study 101
The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism 101
Long-term use of vitamin K antagonists and incidence of cancer: a population-based study 100
Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study 100
Artificial Nutrition and Hydration in Terminally Ill Patients with Advanced Dementia: Opinions and Correlates among Italian Physicians and Nurses 100
A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants 99
Correct laboratory approach to APS diagnosis and monitoring 99
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals 99
APS - controversies in diagnosis and management, critical overview of current guidelines 98
Mild inflammation may switch on again atrial fibrillation after successful electrical cardioversion 98
Cancer as a risk factor for stroke in atrial fibrillation patients receiving long-term oral anticoagulant therapy 98
A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment 97
A combination therapy to treat second-degree anti-ro/la-related congenital heart block. A strategy to avoid stable third-degree heart block? 97
Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. 97
The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study 96
Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study 95
Bidimensional immunoelectrophoresis abnormal migration of serum antithrombin III in coumarin-treated patients. 95
Application of wavelet analysis to the phonocardiographic signal of mechanical heart valve closing sounds 94
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. 94
Worldwide management of oral anticoagulant therapy: the ISAM study 94
Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial 94
A simple scheme to initiate oral anticoagulant treatment in outpatients with nonrheumatic atrial fibrillation 94
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 94
DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register 94
Antiphospholipid syndrome classification criteria: comments on the letter of Swadzba and Musial 93
Confirmation of the initial antiphospholipid antibody positivity depends on antiphospholipid antibody profile 93
Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: Report of four cases and review of the literature 92
Identifying novel thrombin interactions: alpha-synuclein binds to thrombin exosites and inhibits thrombin-mediated platelet aggregation 92
Consequences of warfarin suspension after major bleeding in very elderly patients with non valvular atrial fibrillation 92
Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk 91
Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study 91
Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β2-glycoprotein I is bound to a suitable surface 90
A comparison of lupus anticoagulant-positive patients with clinical picture of Antiphospholipid syndrome and those without 90
Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study 90
Accelerated atherosclerosis in the aortic arch and cerebral ischemia in a patient with primary antiphospholipid syndrome 90
Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective 90
Anti-beta(2)-glycoprotein I ELISA assay: The influence of different antigen preparations 89
A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy 89
Antibody profiles for the diagnosis of antiphospholipid syndrome 89
Family history of venous thrombosis or sudden death as a risk factor for venous thromboembolism. 89
Purification of anticardiolipin and lupus anticoagulant activities by using cardiolipin immobilized on agarose beads. 89
Should patients with mitral stenosis and atrial fibrillation receive combined antithrombotic therapy? 88
Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM) 88
Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial 88
Phonocardiographic classification of mechanical heart valves using artificial neural networks 88
PAIMS-2 - ALTEPLASE COMBINED WITH HEPARIN VERSUS HEPARIN IN THE TREATMENT OF ACUTE PULMONARY-EMBOLISM - PLASMINOGEN-ACTIVATOR ITALIAN MULTICENTER STUDY-2 87
A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome 87
Sixth meeting of the European Forum on antiphospholipid antibodies. How to improve the understanding of the antiphospholipid syndrome? 87
Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes 87
β2-Glycoprotein I Binds to Thrombin and Selectively Inhibits the Enzyme Procoagulant Functions 87
Diabetic ketosis activates lymphomonocyte-inducible nitric oxide synthase. 87
Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: A pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP) 87
Detection of lupus anticoagulant in the era of direct oral anticoagulants 87
Totale 10.390
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.370
article - articoli 84.450
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.343
Totale 177.163
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.991 0 0 0 0 0 0 589 706 625 548 220 303
2020/20213.580 134 339 94 341 112 407 118 341 560 227 472 435
2021/20224.305 127 444 556 389 129 232 177 503 214 90 479 965
2022/20232.947 740 248 53 327 500 351 9 199 342 21 113 44
2023/20241.196 63 203 136 74 69 105 72 70 50 20 156 178
2024/20251.841 19 373 329 194 796 115 15 0 0 0 0 0
Totale 25.041